| 摘要 |
Disclosed is a pharmaceutical composition comprising: a) an omega-3 fatty acid (selected from the group consisting of cis 5, 8, 11, 14, 17-eicosapentanoic acid (EPA) and cis 4, 7, 10, 13, 16, 19-docosahexanoic acid (DHA)): from 500 mg to 2 g/day; b) simvastatin: from 10 mg to 40 g/day; c) coenzyme Q10: from 5 mg to 50 mg/day; d) resveratroI: from 1 mg to 5 mg/day; e) policosanols: hexacosanoI: from 5 mg to 15 mg/day; f) pantethine: from 10 mg to 30 mg/day; g) selenium: from 25 mg to 75 mg/day; h) zinc: from 5 mg to 15 mg/day; wherein the composition may be in the form of a food supplement for human or animal use. Also disclosed is the use of the composition for the preparation of a medicament for the treatment of type 2 diabetes and insulin resistance. Additionally, the use of the composition for the preparation of a medicament useful for the treatment of diseases involving insulin resistance, wherein said disease is selected from the group consisting of type 2 diabetes and its complications, syndrome X, polycystic ovary syndrome, obesity, hypertension, hyperlipidaemias and hypercholesterolaemias is further disclosed. |
